Drug Approval | February 24, 2024
Orchid Pharma's 'Exblifep' receives USFDA approval
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
The agreement sets terms under which POC will manufacture the product or receive royalties
Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Submission to be reviewed under FDA real-time oncology review and Project Orbis
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Subscribe To Our Newsletter & Stay Updated
